Modified Morbillivirus V proteins
AssigneeWyeth Holdings Corporation
InventorChristopher L. Parks
Life of this patent
Estimating the term…
Abstract
Modified Morbilliviruses having at least one mutation in the region corresponding to amino acids 112-134 of the measles virus V protein are described, wherein one or both of amino acids 113 or 114 is mutated. Such modified Morbilliviruses exhibit reduced repression of gene expression. Additional mutations or deletions in other regions of the genome may be included, including in the carboxy-terminal region.
Claims34
An isolated, recombinantly-generated, nonsegmented, negative-sense, single-stranded RNA virus of the genus Morbillivirus having at least one mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein, wherein the mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein is selected from the group consisting of the mutation of amino acids 113 and 114.
An immunogenic composition comprising an isolated, recombinantly-generated, nonsegmented, negative-sense, single-stranded RNA virus of the genus Morbillivirus having at least one mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein, wherein the mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein is selected from the group consisting of the mutation of amino acids 113 and 114, together with a diluent or carrier.
A method for reducing the repression caused by a V protein of the genus Morbillivirus which comprises inserting at least one mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein, wherein the mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein is selected from the group consisting of the mutation of amino acids 113 and 114.
An isolated nucleotide sequence encoding a Morbillivirus V protein which has been modified by inserting at least one mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein, wherein the mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein is selected from the group consisting of the mutation of amino acids 113 and 114.
A composition which comprises a transcription vector comprising an isolated nucleic acid molecule encoding a genome or antigenome of a Morbillivirus, wherein the portion of the isolated nucleic acid molecule encoding the V protein has been modified so as to insert at least one mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein, wherein the mutation in the region corresponding to amino acids 112-134 of a Morbillivirus V protein is selected from the group consisting of the mutation of amino acids 113 and 114, together with at least one expression vector which comprises at least one isolated nucleic acid molecule encoding the trans-acting proteins N, P and L necessary for encapsidation, transcription and replication, whereby upon expression an infectious Morbillivirus is produced.
Dependencies are inferred from the claim text.